Seth Lederman
33Patents
9h-index
27Co-inventors
75Inventor score
Filing activity: Nov 15, 1991 → Dec 5, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5756710A | Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof | Chemistry; Metallurgy | 119 | Expired |
| US5474771A | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same | Emerging Cross-Sectional Technologies | 70 | Expired |
| US6358944B1 | Methods and compositions for treating generalized anxiety disorder | Emerging Cross-Sectional Technologies | 57 | Expired |
| US8093300B2 | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism | Human Necessities | 17 | Active |
| US9474728B2 | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine | Human Necessities | 15 | Active |
| US6340459B1 | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients | Emerging Cross-Sectional Technologies | 12 | Expired |
| US9918948B2 | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine | Human Necessities | 10 | Active |
| US6451310B1 | Method for inhibiting an allergic response with a 5c8-specific antibody | Emerging Cross-Sectional Technologies | 10 | Expired |
| US10357465B2 | Eutectic formulations of cyclobenzaprine hydrochloride | Human Necessities | 9 | Active |
| US6403091B1 | Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies | Emerging Cross-Sectional Technologies | 9 | Expired |
| US7070777B1 | Method for inhibiting inflammation with an antibody that binds the 5C8 protein | Human Necessities | 8 | Expired |
| US5993816A | Methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5c8-specific antibodies | Emerging Cross-Sectional Technologies | 7 | Expired |
| US11026898B2 | Eutectic formulations of cyclobenzaprine hydrochloride | Human Necessities | 4 | Active |
| US6610294B1 | Methods of inhibiting an autoimmune response in a human suffering from an autoimmune disease by administering an antibody that binds to a protein to which monoclonal antibody 5C8 binds | Emerging Cross-Sectional Technologies | 4 | Expired |
| US6331615A | Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) | Emerging Cross-Sectional Technologies | 2 | Expired |
| US6793924B2 | Protein recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8. | Emerging Cross-Sectional Technologies | 2 | Expired |
| US10722478B2 | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine | Human Necessities | 2 | Active |
| US6592868B1 | Methods for treating autoimmune diseases with 5C8-specific antibodies | Emerging Cross-Sectional Technologies | 2 | Expired |
| US6455044B1 | 5c8 antigen | Emerging Cross-Sectional Technologies | 2 | Expired |
| US11207511B2 | Methods for treating baldness and promoting hair growth | Human Necessities | 1 | Active |
| US11826321B2 | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | Human Necessities | 1 | Active |
| US6331433A | Human T cell leukemia cell line designated D1.1 | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6822070B2 | Truncated CRAF1 inhibits CD40 signaling | Emerging Cross-Sectional Technologies | 0 | Expired |
| US9403755B2 | Isometheptene isomer | Chemistry; Metallurgy | 0 | Active |
| US6410710B1 | Nucleic acid encoding a TRAF-3 deletion isoform | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.